Home › Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety...
 

Keywords :   


Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety...

2015-02-27 16:20:00| Appliances - Topix.net

CAMBRIDGE, Mass. & STOCKHOLM-- -- Biogen Idec and Swedish Orphan Biovitrum AB today announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of ALPROLIXA [Coagulation Factor IX , Fc Fusion Protein] in children under age 12 with severe hemophilia B. ALPROLIX was generally well tolerated and no inhibitors were detected during the study.

Tags: positive safety announce efficacy

Category:Consumer Goods and Services

Latest from this category

All news
28.11UK electric car output drops with firms under 'intense pressure'
28.11Mark Zuckerberg dines with Donald Trump at Mar-a-Lago
28.11White Peaks Solutions selects NPAW video analytics
28.11NBCUniversal and Walmart embed shoppable experiences in live sports
28.11Skyline IPTV/OTT service quality monitoring for Bouygues Telecom
28.11Agile Content powers Linkem My Ti-Vi streaming service in Italy
28.11Unite pushes judicial review on winter fuel cuts
28.11Uber questioned by US regulator over subscription plan
Consumer Goods and Services »
28.11LOONA 44
28.11 703g
28.11////HD-218
28.11
28.11
28.11BANDAGE
28.11V6836
28.11 78rpm BILL HALEY 10 SP
More »